Results to be Presented at the European Society for Cardiology Congress Demonstrate Differential Effects During Endothelial Dysfunction in Cell Studies A manuscript entitled “Metabolic, Intestinal, ...
THE WOODLANDS, Texas, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (LXRX) today announced the outcome of the U.S. Food and Drug Administration (FDA) Endocrinologic and Metabolic ...
FDA staff raised familiar safety concerns about sotagliflozin as a treatment for type 1 diabetes (T1D) as the agency again considers an approval, though now for just a subset with chronic kidney ...
An FDA panel on Thursday recommended against sotagliflozin as an adjunct to insulin for patients with type 1 diabetes (T1D) and mild-to-moderate chronic kidney disease (CKD). With a vote of 11-3, the ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Sotagliflozin was linked to lower HbA1c for users with ...
Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart ...
Top-line results show some promise for a completely new, but still investigational, oral agent, sotagliflozin, in people with type 1 diabetes. Sotagliflozin is a first-in-class, oral dual inhibitor of ...
Time to clinical benefit was assessed. The x-axis represents time from randomization, and the y-axis represents the degree of benefit at that time, as measured by the hazard ratio shown in blue. The ...
THE WOODLANDS, Texas, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (LXRX) (Nasdaq: LXRX) today announced that the Company has submitted additional clinical data to the U.S. Food ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results